Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease-Reference-Cited by-同舟云学术

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease

Published:2021-05-12 Issue:593 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Ayalon Gai¹^ORCID,Lee Seung-Hye¹^ORCID,Adolfsson Oskar²^ORCID,Foo-Atkins Corinne³,Atwal Jasvinder K.¹^ORCID,Blendstrup Mira⁴,Booler Helen⁵,Bravo Joseph⁵^ORCID,Brendza Robert¹,Brunstein Flavia⁶,Chan Ruby⁷,Chandra Priya⁸,Couch Jessica A.³,Datwani Akash⁹^ORCID,Demeule Barthélemy¹⁰^ORCID,DiCara Danielle¹¹,Erickson Rich⁹,Ernst James A.⁷,Foreman Oded¹²,He Dongping¹³^ORCID,Hötzel Isidro¹¹^ORCID,Keeley Michael³,Kwok Michael C. M.⁷^ORCID,Lafrance-Vanasse Julien⁷^ORCID,Lin Han¹^ORCID,Lu Yanmei¹³,Luk Wilman¹³^ORCID,Manser Paul¹⁴^ORCID,Muhs Andreas²,Ngu Hai¹²,Pfeifer Andrea²,Pihlgren Maria²^ORCID,Rao Gautham K.⁵,Scearce-Levie Kimberly¹^ORCID,Schauer Stephen P.¹⁵^ORCID,Smith William B.¹⁶^ORCID,Solanoy Hilda¹,Teng Edmond⁴^ORCID,Wildsmith Kristin R.¹⁵,Bumbaca Yadav Daniela¹⁷,Ying Yong⁹^ORCID,Fuji Reina N.⁵^ORCID,Kerchner Geoffrey A.⁴^ORCID

Affiliation:

1. Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA.

2. AC Immune SA, EPFL Innovation Park, Building B, CH-1015 Lausanne, Switzerland.

3. Project Team Leadership, Genentech Inc., San Francisco, CA 94080, USA.

4. Department of Early Clinical Development, Genentech Inc., San Francisco, CA 94080, USA.

5. Department of Safety Assessment, Genentech Inc., San Francisco, CA 94080, USA.

6. Department of Licensing and Early Development Safety, Genentech Inc., San Francisco, CA 94080, USA.

7. Department of Protein Chemistry, Genentech Inc., San Francisco, CA 94080, USA.

8. Department of Clinical Pharmacology, Genentech Inc., San Francisco, CA 94080, USA.

9. Department of Bioanalytical Sciences, Genentech Inc., San Francisco, CA 94080, USA.

10. Department of Late Stage Pharmaceutical Development, Genentech Inc., San Francisco, CA 94080, USA.

11. Department of Antibody Engineering, Genentech Inc., San Francisco, CA 94080, USA.

12. Department of Pathology, Genentech Inc., San Francisco, CA 94080, USA.

13. Department of Biochemical and Cellular Pharmacology, Genentech Inc., San Francisco, CA 94080, USA.

14. Biostatistics, Genentech Inc., San Francisco, CA 94080, USA.

15. Department of Biomarker Development, Genentech Inc., San Francisco, CA 94080, USA.

16. Alliance for Multispecialty Research, University of Tennessee Medical Center, Knoxville, TN 37920, USA.

17. Department of Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc., San Francisco, CA 94080, USA.

Abstract

Semorinemab shows beneficial effects in preclinical models and engages tau in a phase 1 study of patients with Alzheimer’s disease.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference68 articles.

1. Alzheimer’s disease facts and figures; www.alz.org/alzheimers-dementia/facts-figures. (2019).

2. Alzheimer's disease drug development pipeline: 2018

3. A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

4. Clinical trial of an inhibitor of RAGE-A interactions in Alzheimer disease

5. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in Alzheimer's disease: from basic research to diagnosis and therapies;Translational Neurodegeneration;2024-09-04

2. Alzheimer’s disease and immunotherapy;Current Medicine;2024-08-23

3. Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review;ACS Chemical Neuroscience;2024-08-22

4. Time-Dependent Long-Term Effect of Memantine following Repetitive Mild Traumatic Brain Injury;Journal of Neurotrauma;2024-07-01

5. Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders;International Journal of Molecular Sciences;2024-06-18